Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIM8 adjuvant vemurafenib in resected BRAF-mutant melanoma
2011-004011-24Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cutaneous melanoma (CM) and melanoma comparing Vemurafenib with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Jul 2012; status: completed.
02
Drugs
vemurafenib
03
Conditions
cutaneous melanoma (CM)melanoma
Beyond the preview
Go deeper on 2011-004011-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004011-24.